CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program

Rhea-AI Summary

CytoMed Therapeutics (NASDAQ: GDTC), a Singapore-based clinical stage biopharmaceutical company, has announced an At-the-Market (ATM) offering program to raise up to $4.3 million through R.F. Lafferty & Co. as sales agent.

The company will determine the timing and amount of share sales based on market conditions and capital needs. Proceeds will support general corporate purposes, business development initiatives, capital expenditures, and potential strategic acquisitions. Additionally, CytoMed reported that its recently acquired cord blood bank has attracted 2,500 new customers since its acquisition in August 2024, contributing to 2025 revenue.

Positive

• Flexibility in timing and amount of share sales through ATM program
• Cord blood bank acquisition showing success with 2,500 new customer sign-ups
• Multiple potential uses for proceeds including business development and strategic acquisitions

Negative

• Potential dilution for existing shareholders through ATM offering
• No definitive agreements for strategic investments or acquisitions yet
• Share offering indicates need for additional capital

Insights

Financial Analyst

CytoMed announces $4.3M ATM offering to fund corporate initiatives while newly acquired cord blood bank shows customer growth.

CytoMed Therapeutics has established an At-the-Market (ATM) offering program that will allow the company to raise up to $4.3 million by selling ordinary shares through R.F. Lafferty & Co. This financing mechanism gives the company significant flexibility to raise capital gradually based on market conditions rather than conducting a traditional one-time offering. The modest size of this ATM program ($4.3 million) suggests a measured approach to fundraising that may help minimize immediate dilution compared to a single large offering.

The company's stated use of proceeds encompasses general corporate purposes, business diversification, development initiatives, and capital expenditures. Notably, management has explicitly mentioned exploring potential acquisitions or strategic investments in complementary businesses or technologies, signaling possible expansion beyond their current operational scope. This suggests CytoMed is actively looking to strengthen its position in the cell therapy space through inorganic growth.

An important operational update included in the release indicates their recently acquired cord blood bank has generated approximately 2,500 new customer sign-ups since its acquisition in August 2024. This cord blood banking service represents a diversified revenue stream that complements CytoMed's core focus on developing donor-derived cell-based therapies. The cord blood business provides near-term revenue while the company advances its longer-term clinical pipeline, potentially extending their financial runway as they work toward commercializing their cancer therapies.

SINGAPORE, Aug. 18, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the affordable treatment of blood and solid cancers, is pleased to announce that it entered into an At-the-Market Sales Agreement (the “Sales Agreement”) with R.F. Lafferty & Co., Inc. (the “Agent”), as the sales agent.

Pursuant to the Sales Agreement, the Company may offer and sell through the Agent, ordinary shares, no par value (the “Shares”), of the Company having an aggregate value of up to U.S.$4,304,945. The timing and amount of any sales of Shares under the ATM program will be determined by the Company at its discretion, depending on market conditions and the Company’s capital requirements.

The Company intends to use the proceeds from the ATM program for general corporate purposes, which may include business diversification and development initiatives and capital expenditures. We may also use a portion of the net proceeds from this offering to appoint professionals to explore potential acquisitions or strategic investments in complementary businesses or technologies. However as of the date of this press release, the Company has not entered into any definitive agreements. The Company will provide updates to shareholders as additional information becomes available. In the event that any net proceeds are not immediately applied, we may temporarily hold them as cash or deposit them in banks. For information, the Company’s newly acquired cord blood bank has seen approximately 2,500 new customer sign-ups since acquiring it in August 2024, contributing to revenue in 2025.

About CytoMed Therapeutics Limited (CytoMed)

Incorporated in 2018, CytoMed was spun off from the Agency for Science, Technology and Research (A*STAR), Singapore’s leading research and development agency in the public sector. CytoMed is a clinical stage biopharmaceutical company focused on harnessing its licensed proprietary technologies, namely gamma delta T cell and iPSC-derived gamma delta Natural Killer T cell, to create novel cell-based allogeneic immunotherapies for the treatment of various human cancers. The development of novel technologies has been inspired by the clinical success of existing CAR-T therapies in treating haematological malignancies, as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumours. For more information, please visit www.cytomed.sg and follow us on Twitter (“X”) @CytomedSG, on LinkedIn, and Facebook.

Forward-Looking Statements

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company’s plans to develop and commercialize its product candidates; the initiation, timing, progress and results of the Company’s current and future pre-clinical studies and clinical trials and the Company’s R&D programs; the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s ability to successfully acquire or obtain licenses for additional product candidates on reasonable terms; the Company’s ability to establish and maintain collaborations and/or obtain additional funding and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof.

Contact :

CytoMed Therapeutics Limited
enquiry@cytomed.sg
Attention : Evelyn Tan, Chief Corporate Officer

FAQ

How much can CytoMed Therapeutics (GDTC) raise through its ATM offering program?

CytoMed can raise up to $4,304,945 through the ATM offering program with R.F. Lafferty & Co. as the sales agent.

What will CytoMed Therapeutics use the ATM offering proceeds for?

The proceeds will be used for general corporate purposes, business development initiatives, capital expenditures, and exploring potential strategic acquisitions or investments in complementary businesses.

How many new customers has CytoMed's cord blood bank acquired since August 2024?

The cord blood bank has attracted 2,500 new customer sign-ups since its acquisition in August 2024, contributing to revenue in 2025.

Who is the sales agent for CytoMed Therapeutics' ATM offering?

R.F. Lafferty & Co., Inc. serves as the sales agent for the ATM offering program.

When will CytoMed Therapeutics sell shares under the ATM program?

The timing and amount of share sales will be determined by CytoMed at its discretion, based on market conditions and capital requirements.